Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) shares traded up 2.5% during trading on Monday . The company traded as high as $12.70 and last traded at $12.49. 41,848 shares were traded during mid-day trading, a decline of 48% from the average session volume of 80,587 shares. The stock had previously closed at $12.18.
Wall Street Analyst Weigh In
Separately, HC Wainwright upped their target price on Greenwich LifeSciences from $38.00 to $39.00 and gave the company a "buy" rating in a research report on Monday, April 21st.
View Our Latest Analysis on GLSI
Greenwich LifeSciences Stock Performance
The stock has a fifty day simple moving average of $10.51 and a two-hundred day simple moving average of $10.63. The stock has a market cap of $162.45 million, a price-to-earnings ratio of -9.63 and a beta of 1.65.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.06). Equities analysts expect that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in GLSI. GAMMA Investing LLC bought a new position in shares of Greenwich LifeSciences in the first quarter valued at approximately $126,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Greenwich LifeSciences in the second quarter worth $25,000. Wells Fargo & Company MN boosted its holdings in shares of Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company's stock worth $32,000 after acquiring an additional 1,008 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company's stock worth $79,000 after acquiring an additional 4,465 shares during the period. Finally, Bank of America Corp DE boosted its holdings in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after acquiring an additional 1,322 shares during the period. 4.16% of the stock is owned by institutional investors.
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Articles
Before you consider Greenwich LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.
While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
